Business World

Wednesday 13 December 2017

Pharmaceutical group Shire is seeking to buy US firm Baxalta in a $30bn all-share deal

Shares in Shire were down 8pc
Shares in Shire were down 8pc

London-listed, Dublin headquartered pharmaceutical group Shire is seeking to buy US firm Baxalta in a $30bn all-share deal to create a global specialist in medicines treating rare diseases with sales of $20bn by 2020.

Shire went public with its proposal today after Baxalta rejected the approach.

Shire said it had offered to pay 0.1687 Shire ADR for each Baxalta share, implying a value of $45.23 per Baxalta share and a premium of 36pc over Baxalta's stock price as on August 3.

Shares in Shire were down 8pc on the news.

Reuters

Promoted Links

Business Newsletter

Read the leading stories from the world of Business.

Promoted Links

Also in Business